Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 347

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 347
---
 plans to build on partnerships through our strategic consortium. Heritas Argentina has been a genomics pioneer in Latin America for over eight years with proprietary developed tests and prevention services, primarily distributed through partnerships. By combining the strengths of our current and future partnerships, we expect to position ourselves as a leading AI -enabledgenomics company. OmnigenicsAI’s expertise spans biological, scientific, technological and market know -how, all of which are critical for product development and execution. Supported by a diverse and specialized team, we are crafting a highly complementary and comprehensive product portfolio that addresses a broad spectrum of health needs. We believe we are pioneering the integration of genomic testing results with clinical and lifestyle data in the region. This combination creates enriched genomic datasets filled with potential insights, which we expect to be disruptive of patient’s healthcare, specially, since there are no data sets built from Latin American genes, a population not only present in the region, but is growing globally as well. OmnigenicsAI expects to commercialize its product portfolio through two brands: (i) Rewell, offering wellness and prevention solutions for consumers, and (ii) Heritas Diagnostics offering precise clinical genetic services for patients and physicians. This portfolio aims to address various aspects of healthcare, targeting the general population through Rewell for preventative measures and secondary care through Heritas for diagnostic services. We currently employ AI by including machine learning models and third party LLMs that routinely assist in data analysis and service delivery, subject to rigorous validation and monitoring. The end -to -enddata we collect from our comprehensive services suite is actively used to train and improve these AI systems, and we are implementing controls and procedures designed to protect sensitive data. Looking ahead, within the next five years we plan to develop more sophisticated AI -poweredtools and complex models that will increasingly provide broader support for health management, clinical research, drug discovery studies and clinical trials while working to meet evolving regulatory requirements and industry standards for AI in healthcare. Heritas Argentina On July 10, 2015, Heritas Argentina was incorporated in Argentina by Fabian Fay and Martin Pablo Vazquez under registration number T98 F252 N12, establishing itself in the field of personalized medicine services focused on human genomics solutions, as well as conducting clinical studies and medical and veterinary analyses. Pursuant to the shareholders’ agreement dated December 27, 2016, the initial shareholders of Heritas Argentina were Messrs. Fay and Vazquez, each holding 17% of Heritas Argentina, and CIBIC and Instituto de